Accelerate Diagnostics (NASDAQ: AXDX) and Luna Innovations (NASDAQ:LUNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
This is a breakdown of current ratings for Accelerate Diagnostics and Luna Innovations, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accelerate Diagnostics currently has a consensus price target of $33.00, suggesting a potential upside of 29.92%. Luna Innovations has a consensus price target of $3.00, suggesting a potential upside of 16.73%. Given Accelerate Diagnostics’ higher probable upside, analysts plainly believe Accelerate Diagnostics is more favorable than Luna Innovations.
This table compares Accelerate Diagnostics and Luna Innovations’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
44.9% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 18.1% of Luna Innovations shares are held by institutional investors. 50.0% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 13.0% of Luna Innovations shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Accelerate Diagnostics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Earnings and Valuation
This table compares Accelerate Diagnostics and Luna Innovations’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Accelerate Diagnostics||$4.18 million||338.89||-$64.02 million||($1.18)||-21.53|
|Luna Innovations||$59.21 million||1.23||-$2.36 million||N/A||N/A|
Luna Innovations has higher revenue and earnings than Accelerate Diagnostics.
Luna Innovations beats Accelerate Diagnostics on 7 of the 12 factors compared between the two stocks.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
About Luna Innovations
Luna Innovations Incorporated develops, manufactures and markets fiber optic sensing and test, and measurement products. The Company is focused on bringing technology solutions to measure and monitor processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. The Company operates in two business segments: Products and Licensing, and Technology Development. The Products and Licensing segment develops, manufactures and markets its suite of products, including high-speed optical receiver (HSOR), custom optoelectronic subsystems (Optoelectronics), and Terahertz (THz) products, and fiber optic sensing, as well as test and measurement products. The Technology Development segment performs applied research principally in the areas of sensing and instrumentation, advanced materials and health sciences. The Company’s HSOR transmission products are deployed in the Internet communications equipment infrastructure for high-speed bandwidth.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.